Mirabegron for overactive bladder: Added benefit not proven

Mirabegron has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, experts examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee. No added benefit has been proven.